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Abstract
Background—The epidemiology of antibiotic-resistant Enterobacteriaceae intestinal carriage in 
healthy US children has not been well characterized.
Methods—Children between 14 days and 14 years of age were enrolled during well-child visits 
in Oakland, California, Kansas City, Kansas, and Nashville, Tennessee, between December 2013 
and March 2015. Data on recent antibiotic use by the child and travel and hospitalization history of 
all members of each child’s household were obtained with a risk-factor survey. Stool specimens 
collected from the subjects were screened for extended-spectrum β-lactamase-producing (ESBL-
P) bacteria using CHROMagar ESBL medium. Putative ESBL-P Escherichia coli and Klebsiella 
colonies underwent phenotypic confirmation by double-disk synergy testing; confirmed third-
generation cephalosporin-resistant (3GCR) isolates underwent additional antibiotic-susceptibility 
testing.
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Results—In 519 subjects, the overall 3GCR Enterobacteriaceae carriage rate was 4.4% (n = 23) 
and ranged from 3.4% to 5.1% among the study sites. The ESBL-P Enterobacteriaceae carriage 
rate was 3.5% (n = 18). The rates of 3GCR Enterobacteriaceae carriage was highest in 1 to <2 year 
olds at 6.5%, and was 5.2% in <5 year-olds vs 1.7% in ≥5-year-olds (P = .11). 3GCR and ESBL-P 
Enterobacteriaceae carriage was associated with international travel within the previous year; 
11.1% of ESBL-P Enterobacteriaceae carriers reported this history compared with 1.6% of 
noncarriers (P = .004). No other queried factor was found to increase risk. Of the 24 analyzed 
3GCR isolates, 58% were multidrug resistant.
Conclusions—The 3GCR Enterobacteriaceae carriage rate exceeds 5% in healthy US children 
<5 years of age. International travel within the previous year increased the risk of 3GCR and 
ESBL-P Enterobacteriaceae carriage. In contrast, we found no differences in the rates of 
hospitalization or recent antibiotic exposure between carriers and noncarriers. Young children, 
who have the highest prevalence of colonization, might be a sentinel population to study to gain a 
better understanding of community sources of antibiotic-resistant Enterobacteriaceae.
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ESBL-producing Enterobacteriaceae intestinal carriage; extended-spectrum β-lactamase (ESBL); 
multidrug-resistant Gram-negative bacteria; third-generation cephalosporin-resistant 
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Infections caused by extended-spectrum β-lactamase-producing (ESBL-P) 
Enterobacteriaceae and other antibiotic-resistant (AR) Gram-negative bacteria are steadily 
rising in various healthcare settings [1–3]. This trend includes children; US laboratory 
surveillance data between 1999 and 2011 revealed a 3- to 5-fold increase in the proportions 
of pediatric Gram-negative bacterial isolates that were ESBL-P or third-generation 
cephalosporin resistant (3GCR) (to 0.92% and 3%, respectively) [3]. Although inpatient 
carriage rates for ESBL-P Enterobacteriaceae are the highest and exceed 10% in many 
intensive care units, individual cases frequently originate in the community and in patients 
without significant medical comorbidity [3–5]. 3GCR and ESBL-P Enterobacteriaceae 
infections are often multidrug resistant, and management in children can be particularly 
challenging because of the limited therapeutic options [5].
Asymptomatic intestinal carriage of AR Enterobacteriaceae can both follow and precede 
clinical infection [5–7]. Risk factors for acquisition and colonization of AR 
Enterobacteriaceae in children are not well characterized; the studies that are available 
identified primarily carriers after an index infection and found underlying neurologic and 
other medical conditions, along with recent antibiotic intake, to be predisposing factors [5–
9]. In adults, foreign travel—particularly to certain regions and even after relatively short 
trips—has been associated with significant rates of new fecal carriage of ESBL-P bacteria 
[10–13]. Similarly, it has been increasingly recognized that the widespread, global 
dissemination of ESBLs at the general population level (particularly of the CTX-M 
enzymes) has resulted in communities with a high prevalence of ESBL carriers [14].
Community-based studies of pediatric AR Enterobacteriaceae carriage have revealed rates 
that vary widely, from <3% in young Swedish children (ESBL-P) to 4% to 8% in the 
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Netherlands (3GCR) and >20% in sites in Spain and Africa (ESBL-P) [15–18]. From North 
America, however, AR bacterial intestinal carriage data at the community level are generally 
lacking, especially in children [14]. In this investigation, fecal specimens of healthy children 
from 3 urban US centers were tested for the presence of ESBL-P and 3GCR 
Enterobacteriaceae to determine rates of intestinal carriage. Basic healthcare exposures and 
travel in household (HH) members were queried and analyzed as risk factors for 
colonization. In addition, recovered 3GCR Enterobacteriaceae isolates were tested for 
susceptibility to relevant antibiotic classes.
METHODS
Study Design and Participants
This investigation was conducted as a substudy of a larger multicenter study on the 
epidemiology of pediatric gastroenteritis by the New Vaccine Surveillance Network 
(NVSN), funded by the US Centers for Disease Control and Prevention. Subjects of this AR 
Enterobacteriaceae colonization study were included after being enrolled as healthy controls 
in the primary NVSN study. Participating sites in this study were UCSF Benioff Children’s 
Hospital Oakland in Oakland, California (OAK), Children’s Mercy Hospital in Kansas City, 
Missouri, (KC), and Monroe Carrel Jr. Children’s Hospital at Vanderbilt in Nashville, 
Tennessee (NASH).
Children between 14 days and 14 years of age were enrolled during well-child visits at their 
primary clinic. As healthy controls in the NVSN study, exclusion criteria were being 
immunocompromised, having had diarrhea or vomiting in the previous 14 days, and having 
had acute respiratory infection symptoms in the previous 3 days. Participants of this 
substudy underwent a brief survey that queried antibiotic intake by the child in the previous 
3 months and international travel and/or hospitalization in any HH member and foreign 
visitors to the HH in the previous year (see the questionnaire in Supplementary Appendix).
Specimen Processing, Laboratory Analyses, and Definitions
According to the protocol of the NVSN study, stool specimens from the subject typically 
were obtained at the time of enrollment; when this was not possible, families were provided 
a container in which to collect and submit stool within 5 days by either direct drop-off at the 
study site or a study-arranged courier. After stool receipt, a separate aliquot of 
approximately 1 g/0.5 ml of stool was prepared in a 1-ml solution of sterile Luria broth with 
20% glycerol specifically for this AR Enterobacteriaceae colonization study.
For initial screening for the presence of AR Enterobacteriaceae, 1 µL of the stool solution 
described above was streaked directly onto ESBL CHROMagar (CHROMagar, Paris, 
France) medium plates. The ESBL CHROMagar medium and plates were prepared from a 
prep powder according to product instructions at each of the 3 sites. Preparation of the stool 
solution and inoculation onto the ESBL CHROMagar medium plates typically were 
performed on the day of stool receipt; in the infrequent situation when this process was not 
possible (eg, specimen received on the weekend or another time when the laboratory 
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coordinator was not available), the prepared stool aliquots were generally maintained at 2 to 
8°C and tested within 2 to 3 days.
Inoculated ESBL CHROMagar plates were incubated at 37°C for 18 to 24 hours and then 
assessed for colony growth. Klebsiella pneumoniae (strain ATCC 700603) and Escherichia 
coli (strain ATCC 25922) were used as positive and negative controls, respectively. Non–
ESBL-P bacteria are inhibited by ESBL CHROMagar medium; colonies that grow are 
putative ESBL producers, and different species have distinct colors [19]. Putative ESBL-P E 
coli and Klebsiella colonies were subcultured to establish pure colonies, which were placed 
in Luria broth with 20% glycerol and maintained at −80°C until further analysis. Matrix-
assisted laser desorption/ionization–time-of-flight mass spectrometry (Bruker Daltonics, Inc, 
Billerica, MA) was performed on all putative (CHROMagar medium-recovered) ESBL-P 
Enterobacteriaceae colonies for bacteriologic species identification/confirmation.
All putative ESBL-P E coli and Klebsiella colonies underwent standard double-disk synergy 
testing on Muller-Hinton agar (BD Difco, Sparks, MD) following Clinical Laboratory 
Standards Institute (CLSI) guidelines [20]. Briefly, bacterial colonies were tested with the 
third-generation cephalosporins cefotaxime (30 µg) and ceftazidime (30 µg) alone and in 
combination with clavulanic acid (10 µg); the ESBL phenotype was defined as a ≥5-mm 
increase in the zone of inhibition with the combination of a third-generation cephalosporin 
with clavulanic acid when compared to the third-generation cephalosporin alone. Third-
generation cephalosporin resistance was defined as nonsusceptibility (intermediate 
susceptibility or resistance) to either cefotaxime or ceftazidime (nonsusceptible zones of 
inhibition: cefotaxime, <23 mm; ceftazidime, <18 mm).
All confirmed 3GCR and ESBL-P E coli and Klebsiella isolates underwent additional 
antibiotic testing on Muller-Hinton agar with disks of amoxicillin-clavulanic acid, 
piperacillin-tazobactam, trimethoprim-sulfamethoxazole, aztreonam, nalidixic acid, 
meropenem, ampicillin, cephalothin, ceftriaxone and cefepime (BD BBL, Franklin Lakes, 
NJ) and ciprofloxacin, tetracycline, cefaclor, gentamicin, amikacin, and imipenem (Hardy 
Diagnostics, Santa Maria, CA). Antimicrobial zones of inhibition were interpreted according 
to CLSI guideline breakpoints [20]. Multidrug resistance was defined as nonsusceptibility to 
≥1 agent in ≥3 antimicrobial classes.
Statistics
Sample sizes for analysis and subject enrollment targets were governed primarily by 
feasibility considerations and what was anticipated to be achievable during a remaining year 
of the main NVSN surveillance study. Also, an absence of baseline data on AR 
Enterobacteriaceae carriage in healthy US children, along with uncertainties in the 
distribution of hypothesized risk factors (eg, proportion of subjects with foreign travel in HH 
members), challenged power calculations. A target of approximately 500 healthy controls 
who had submitted stool specimens was set and divided nearly evenly among the 3 
participating sites.
Intestinal carriage was defined as having the presence of at least 1 colony of the specific AR 
Enterobacteriaceae in the subject’s stool specimen. Descriptive statistics for intestinal 3GCR 
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and ESBL-P Enterobacteriaceae carriage for various demographic groups were generated. 
3GCR and ESBL-P Enterobacteriaceae carriers were compared with noncarriers for 
association with potential risk factors by χ2 testing; statistical significance was set at a P 
value of <.05. The small sample of identified AR Enterobacteriaceae carriers, and subject 
subgroups (eg, according to age or reporting HH international travel), challenged the 
reliability of multivariable methods; thus, these methods were not performed. Statistical 
analysis was performed within the RedCAP 6.13.3 database system (Vanderbilt University) 
and with MedCalc 16.4.3 (MedCalc, Ostend, Belgium).
Ethics
The protocol was approved by the institutional review board/ethics committee at each 
participating site and the Centers for Disease Control and Prevention. Informed consent for 
performing the risk-factor survey and stool specimen laboratory testing was obtained from 
the legal guardians of each participant (all ≤14 years of age).
RESULTS
Between December 2013 and March 2015, a total of 761 subjects from the 3 sites were 
enrolled, and 519 (68.2%) submitted a stool specimen. The median age of the subjects with 
a stool specimen was 18 months; 51.1% were female.
Twenty-three analyzed subjects harbored 3GCR Enterobacteriaceae in their stool, for an 
overall intestinal carriage rate of 4.4%. Site-specific rates varied from 3.4% at OAK to 5.1% 
at KC (Table 1). Of the 3GCR intestinal carriers, 60.9% were female (P = .36). Of the 3GCR 
isolates, 78% (n = 18) were confirmed ESBL-P, and the overall ESBL-P Enterobacteriaceae 
carriage rate was 3.5%. The carriage rates for 3GCR and ESBL-P Enterobacteriaceae in 1- 
to <2-year-old children were 6.5% and 5.7%, respectively (Table 2). The carriage rates for 
3GCR Enterobacteriaceae were 5.2% for <5-year-olds and 1.7% for ≥5-year-olds (P = .11).
Completed risk-factor questionnaires from all 3GCR and ESBL-P Enterobacteriaceae 
carriers and 489 (98.6%) of 496 non-carriers were available; the associations of 3GCR and 
ESBL-P Enterobacteriaceae carriage with queried risk factors are presented in Table 3. 
3GCR and ESBL-P Enterobacteriaceae carriage was associated with HH member foreign 
travel within the preceding year; for ESBL-P Enterobacteriaceae, 11.1% of carriers versus 
1.6% of noncarriers (P = .004) had personal travel abroad. At OAK, where travel rates were 
highest among the 3 sites, 50% (3 of 6) of 3GCR and ESBL-P Enterobacteriaceae carriers 
had a HH travel history versus 11.2% of the noncarriers (P = .005). The countries that 3GCR 
and ESBL-P Enterobacteriaceae carriers and their HH members visited were Mexico, Nepal, 
the Dominican Republic, and Vietnam. Rates of hospitalization in the previous year and of 
having had any antibiotic exposure in the previous 3 months did not differ between carriers 
and non-carriers (for both 3GCR and ESBL-P Enterobacteriaceae).
Two distinct 3GCR Enterobacteriaceae isolates were analyzed from a single carrier; of the 
24 analyzed isolates, 23 were 3GCR E coli, and 1 was Klebsiella pneumoniae. Antibiotic-
susceptibility testing results are presented in Table 4. Seventy-nine percent of the isolates 
were resistant to trimethoprim-sulfamethoxazole, and 58% were resistant to ciprofloxacin. 
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One (4%) isolate was meropenem intermediate. The proportion of 3GCR isolates that were 
multidrug resistant was 58% overall, but it varied substantially among the study sites (KC, 
33%; OAK, 100%; NASH, 56%). All (6) 3GCR Enterobacteriaceae isolates from OAK were 
ESBL-P and were multidrug resistant.
DISCUSSION
In this analysis of 519 healthy children in Oakland, Nashville, and Kansas City, 4.4% were 
carriers of intestinal Enterobacteriaceae resistant to third-generation cephalosporins; 3.5% 
specifically harbored ESBLs. This study is the largest community-based characterization of 
AR Enterobacteriaceae colonization in healthy children from North America to date. It is 
also 1 of very few pediatric studies to have examined international travel as a risk factor for 
either AR Enterobacteriaceae colonization or infection [21].
Previous reports on AR Enterobacteriaceae colonization in healthy children examined 
mainly ESBL-P (rather than 3GCR) Enterobacteriaceae and were primarily from discrete 
sites in Europe, with few from other regions. Although pediatric rates from earlier studies in 
other northern European countries were consistently <7% [15, 22–24], a recent analysis of 
125 well 8- to 16-month-old children in northern Spain found a surprising 24% overall 
prevalence of ESBL-P Enterobacteriaceae colonization [17]. Data from children in Africa 
and Asia, which might inform community-level colonization, are limited but have 
consistently indicated high prevalences; children screened on presentation to medical 
facilities in Niger and Guinea-Bissau had ESBL-P Enterobacteriaceae rates of 32.6% and 
31%, respectively [17, 25], and in nearly 400 healthy <6-year-olds attending childcare 
centers in Laos (2011), the ESBL-P Enterobacteriaceae carriage rate was 23% [26]. Existing 
data from adults in North America itself are minimal, and ESBL community carriage (based 
on travelers before departure [12], healthy military personnel [27], and vegetarians living in 
the Midwest [28]) might be best estimated to be ~2% [29]. In this context, ESBL-P 
Enterobacteriaceae rates found in this study (3.5% overall and 5.7% in children aged 1 to <2 
years) are higher than ever reported in healthy Americans and are generally comparable to 
those in European countries.
In various case-control analyses [30, 31] and in studies that examined fecal carriage of 
travelers before and after trips abroad [10, 13], international travel was found to be a risk 
factor for ESBL-P Enterobacteriaceae colonization and infection in adults. Investigations of 
stool from Scandinavian travelers found that >20% acquire ESBL-P Enterobacteriaceae after 
time abroad (trips typically ~2 weeks); the rates were highest for those who visited 
destinations in Asia and were up to 80% for those who had diarrhea and took antibiotics 
during their journey [10, 13]. A recent comprehensive meta-analysis found that international 
travel conferred a higher risk for ESBL colonization than any other factor (relative risk, >4) 
[29]. A separate systematic review in which available community carriage and population 
census data were used estimated there are >1.1 billion ESBL-P Enterobacteriaceae carriers 
in southeast Asia [14]; these and other authors have described what has become a 
globalization of the CTX-M ESBL enzyme (in particular), with international travel and 
migration being key drivers [14, 31]. The findings of our analysis reflect the existing 
literature in adults; children with a personal history of foreign travel were 5 times more 
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likely to be 3GCR Enterobacteriaceae carriers that those without such as history (20% [2 of 
10] vs 4.1% [21 of 509], respectively; P = .015)
In our study, 3GCR and ESBL-P Enterobacteriaceae carriers and noncarriers had antibiotic 
exposure within the previous 3 months in nearly equal proportions. Although recent 
antibiotic use has been associated with increased risk of ESBL-P Enterobacteriaceae 
colonization in adults [28] and of ESBL infections in children [7–9, 32], previous pediatric 
studies did not show a consistent association of antibiotic intake with fecal ESBL-P 
Enterobacteriaceae carriage [16, 20, 24, 26, 33]. In addition, a history of hospitalization in 
our subjects or in their HH members was not a definitive risk factor for 3GCR or ESBL-P 
Enterobacteriaceae colonization, which also is consistent with data from adults [29]. The 
factors underlying new and sustained fecal carriage of AR bacteria are complex and not fully 
characterized, but they seem to involve gastrointestinal disruption and selective antibiotic 
pressure along with exogenous exposure to AR Enterobacteriaceae [6, 13, 34].
It should be noted that the majority (57% [13 of 23]) of 3GCR Enterobacteriaceae–colonized 
children lacked all the considered risk factors of HH international travel, recent personal 
antibiotic exposure, and HH hospitalization history. These findings support the idea that AR 
Enterobacteriaceae are truly present at the community level and that potential sources, 
including the food supply and general environment, might be widespread and common [14, 
29, 33, 35].
Children have a unique place in the transmission dynamics (both acquisition and transfer) of 
AR bacteria. Infants in particular might have intimate contact with several adult caregivers 
and, by nature, are incontinent, have limited hygiene, and frequently touch materials in their 
environment. The immature neonatal/infant intestine seems particularly vulnerable to AR 
Enterobacteriaceae acquisition; the results of recent studies highlighted the fact that the 
infant microbiome is unstable and frequently populated with AR genes [36, 37]. Young 
children also appear prone to protracted carriage: studies employing molecular techniques of 
ESBL Enterobacteriaceae carrying infants discharged from neonatal intensive care units 
(NICU) [38, 39] and in international adoptees [40] have demonstrated duration of 
colonization of up to 2 years. AR Enterobacteriaceae strains can be regularly spread and 
then sustained within HH and daycare settings; in 1 longitudinal investigation, the 
intrafamilial transmission rate from colonized post–neonatal intensive care unit infants was 
32% [39].
In addition, young children might have higher risk related to AR Enterobacteriaceae carriage 
itself; ~5% of children have at least 1 community-onset urinary tract infection by the age of 
5 years (the pathogens of which, in healthy individuals, are presumed to be from their own 
intestinal flora). This risk is reflected in US clinical laboratory-based surveillance data; 
approximately half of 3GCR and ESBL-P pediatric isolates are from 1- to 5-year-olds, and 
the majority are from urine specimens [3].
Our study has important limitations. As a subinvestigation of a larger study, questions added 
to assess exposures associated with AR Enterobacteriaceae carriage were few and simplistic; 
as a result, the evaluation of potential risk factors is incomplete. In particular, mainly to 
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avoid recall bias, antibiotic exposure was gauged only in the binary fashion of having any or 
none within the previous 3 months; data on specific agent(s) and total duration of exposure 
and more distant antibiotic use, all of which can significantly affect intestinal 
Enterobacteriaceae composition, were not captured. Also, other possible contributors to AR 
Enterobacteriaceae carriage, such as diet, acid-suppressing drugs, and outpatient medical 
exposures, were not queried at all. Regarding international travel, children who visited 
abroad all did so with other HH members, which challenges determining the relative 
contribution of personal versus close-contact foreign travel on pediatric AR 
Enterobacteriaceae carriage. The relatively small number of subjects who reported HH 
member international travel limited closer consideration of destination and timing of travel 
in relation to carriage. Likewise, the small number of 3GCR (n = 23) and ESBL-P (n = 18) 
Enterobacteriaceae carriers limited our study power and did not allow for reliable 
comparisons of some possibly important strata, such as age and geographic site. Lastly, our 
initial specimen screening on a commercial medium and phenotypic (rather than genotypic) 
methods for AR bacterial detection might have failed to capture certain 3GCR or ESBL-P 
Enterobacteriaceae, which in turn would lead to an underestimation of carriage prevalence.
In conclusion, the current 3GCR and ESBL-P Enterobacteriaceae colonization rate in 
healthy US children is appreciable and >5% in specific locations and age groups. 
Acquisition and dissemination are most likely in the HH and community setting and might 
be unrelated to healthcare exposures. In our analysis, pediatric carriers of 3GCR and ESBL-
P Enterobacteriaceae reported 5- to 7-fold-higher rates of international travel than 
noncarriers, which was the only significant risk factor. Young children have distinct risks 
related to 3GCR and ESBL-P Enterobacteriaceae, with what seem to be higher rates of 
acquisition and prolonged carriage, and might serve as an ideal population for additional 
study. With ESBL carriage recently estimated to be rising 5% per year globally [29], the 
issue is a serious public health concern with broad-ranging implications related to optimal 
empiric management of community-onset infections, transnational antibiotic stewardship, 
and infection control.
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Table 1
3GCR, ESBL-P, and MDR Eb Carriage
Site (Total No. of Subjects Tested)
Eb Carriage Rate (% [Total No. of Carriers])
3GCR ESBL-P MDR
Oakland (176) 3.4 (6) 3.4 (6) 3.4 (6)
Kansas City (177) 5.1 (9) 3.4 (6) 1.7 (3)
Nashville (166) 4.8 (8) 3.6 (6) 2.4 (4)
Total (519) 4.4 (23) 3.5 (18) 2.5 (13)
Abbreviations: 3GCR, third-generation cephalosporin resistant; Eb, Enterobacteriaceae; ESBL-P, extended-spectrum β-lactamase producing 
(confirmed by double-disk diffusion testing); MDR, multidrug resistant (defined as nonsusceptible to ≥1 agent in ≥3 antimicrobial classes).
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Table 2
3GCR and ESBL-P Eb Carriage According to Age
Age Group (Total No. of Subjects)
Eb Carriage Rate (% [Total No. of Carriers])
3GCR ESBL-P
0 to <1 y (178) 4.5 (8) 2.2 (4)
1 to <2 y (123) 6.5 (8) 5.7 (7)
2 to <3 y (60) 5.0 (3) 5.0 (3)
3 to <4 y (20) 5.0 (1) 5.0 (1)
4 to <5 y (23) 4.3 (1) 4.3 (1)
5 to <6 y (33) 0 (0) 0 (0)
6 to <7 y (19) 5.3 (1) 5.3 (1)
7 to 14 y (63) 1.6 (1) 1.6 (1)
Abbreviations: 3GCR, third-generation cephalosporin resistant; Eb, Enterobacteriaceae; ESBL-P, extended-spectrum β-lactamase producing 
(confirmed by double-disk diffusion testing).
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